Healthcare - Biotechnology - NASDAQ - US
$ 2.3
-6.5 %
$ 289 M
Market Cap
-4.11
P/E
CASH FLOW STATEMENT
-51.7 M
OPERATING CASH FLOW
-43.7 M
INVESTING CASH FLOW
368 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nautilus Biotechnology, Inc.
| Net Income | -63.7 M |
| Depreciation & Amortization | 5.7 M |
| Capital Expenditures | -2.44 M |
| Stock-Based Compensation | 12.1 M |
| Change in Working Capital | -3.22 M |
| Others | -6.27 M |
| Free Cash Flow | -54.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (63.7) | (57.9) | (50.3) | (15.6) | (9.6) | 626.6 |
| Depreciation & Amortization | 5.7 | 3.4 | 2.8 | 2.3 | 0.5 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0.8 | 0 |
| Stock Based Compensation | 12.1 | 10.4 | 7.9 | 0.4 | 0.1 | 0 |
| Other Operating Activities | (2.7) | (0.9) | 0.3 | 0.3 | (0.2) | (866.2) |
| Change in Working Capital | (3.2) | (0.8) | 22 K | (1.4) | (0.5) | 1.3 |
| Cash From Operations | (51.7) | (45.8) | (39.2) | (14.0) | (9.7) | (238.3) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (2.4) | (2.3) | (2.3) | (0.9) | (0.9) | 0 |
| Other Items | (41.3) | (23.4) | (136.7) | (24.4) | 5.0 | 1.2 |
| Cash From Investing Activities | (43.7) | (25.7) | (139.0) | (25.3) | 4.0 | 1.2 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0.3 | 0.2 | 0 | 0 | (0.9) | (1.2) |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.4 | 0.6 | 327.4 | 75.9 | 36 K | 145 186.6 |
| Cash From Financing Activities | 0.4 | 0.6 | 327.4 | 75.9 | 36 K | 145 186.6 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (95.1) | (71.0) | 149.2 | 36.6 | (1 197.7) | 1.2 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (54.2) | (48.1) | (41.5) | (14.9) | (10.6) | (238.3) |